Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andres Forero-Torres

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Blood|January 17, 2020
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 studyDavid J Straus, Monika Długosz-Danecka, Sergey Alekseev, et al.
Science Translational Medicine|March 18, 2011
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphomaBart Burington, Peng Yue, Xiaoyan Shi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67Bojana Jovanović, Ingrid A Mayer, Erica L Mayer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2023
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast CancerJamunarani Veeraraghavan, Carolina Gutierrez, Carmine De Angelis, et al.
Cancer Cell|May 5, 2023
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapyMark Jesus M Magbanua, Lamorna Brown Swigart, Ziad Ahmed, et al.
NPJ Breast Cancer|May 13, 2021
FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036Steven P Angus, Timothy J Stuhlmiller, Gaurav Mehta, et al.
JAMA Network Open|December 28, 2023
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast CancerBeverly Kyalwazi, Christina Yau, Michael J Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
The Neoadjuvant Model Is Still the Future for Drug Development in Breast CancerAngela DeMichele, Douglas Yee, Donald A Berry, et al.
JAMA Oncology|February 14, 2020
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialRita Nanda, Minetta C Liu, Christina Yau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2021
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical TrialSara M Tolaney, Nabihah Tayob, Chau Dang, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Blood|January 17, 2020
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 studyDavid J Straus, Monika Długosz-Danecka, Sergey Alekseev, et al.
Science Translational Medicine|March 18, 2011
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphomaBart Burington, Peng Yue, Xiaoyan Shi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67Bojana Jovanović, Ingrid A Mayer, Erica L Mayer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2023
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast CancerJamunarani Veeraraghavan, Carolina Gutierrez, Carmine De Angelis, et al.
Cancer Cell|May 5, 2023
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapyMark Jesus M Magbanua, Lamorna Brown Swigart, Ziad Ahmed, et al.
NPJ Breast Cancer|May 13, 2021
FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036Steven P Angus, Timothy J Stuhlmiller, Gaurav Mehta, et al.
JAMA Network Open|December 28, 2023
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast CancerBeverly Kyalwazi, Christina Yau, Michael J Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
The Neoadjuvant Model Is Still the Future for Drug Development in Breast CancerAngela DeMichele, Douglas Yee, Donald A Berry, et al.
JAMA Oncology|February 14, 2020
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialRita Nanda, Minetta C Liu, Christina Yau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2021
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical TrialSara M Tolaney, Nabihah Tayob, Chau Dang, et al.
Pageof 10